Effect of Mycophenolate Mofetil on the Anti-CMV Serologic Response After Renal Transplantation.

Hardwick, Laura L.; Anderson, Melissa J.; Book, Benita K.; McQueen, J.; Milgrom, Martin L.; Savatta, S.G; Pescovitz, Mark D.

doi:10.1097/00007890-200004271-00844

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately the study was very small, with a total enrollment of 33 patients. A retrospective study by Hardwick et al (30) speci¢cally examined CMV IgG levels in renal transplant recipients who received either Aza or MMF and developed CMV disease. They reviewed serum CMV IgG antibody levels as determined by enzyme immunoassay (drawn approximately 1 month after transplantation), and found no di¡erence between the level of CMV IgG in patients on MMF versus Aza (30).…”

Section: CMVmentioning

confidence: 99%

“…A retrospective study by Hardwick et al (30) speci¢cally examined CMV IgG levels in renal transplant recipients who received either Aza or MMF and developed CMV disease. They reviewed serum CMV IgG antibody levels as determined by enzyme immunoassay (drawn approximately 1 month after transplantation), and found no di¡erence between the level of CMV IgG in patients on MMF versus Aza (30). As in the Zmonarski study (18), the authors did not ¢nd a decrease in CMV IgG in patients receiving MMF, but they did not examine CMV IgM levels.…”

Section: CMVmentioning

confidence: 99%

See 1 more Smart Citation

Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity

Ritter

Pirofski

2009

Transplant Infectious Dis

140

View full text Add to dashboard Cite

Mycophenolate mofetil (MMF) is one of the most frequently used immunosuppressive drugs in solid organ transplant recipients. MMF is an inhibitor of inosine-5′-monophosphate, and is able to preferentially inhibit B-cell and T-cell function. The immunosuppressive abilities of MMF have made it one of the most successful anti-rejection drugs in transplant patients, but patients also appear to have increased susceptibility to infections, specifically cytomegalovirus and BKvirus. Despite its association with an increased risk of infection, MMF has also exhibited antimicrobial activity against pathogens including hepatitis C, Pneumocystis jirovecii, and human immunodeficiency virus. A thorough understanding of the functions of MMF on the immune system and interaction with infectious pathogens could be helpful in implementing preventative strategies against opportunistic infections in transplant patients.

show abstract

Section: CMVmentioning

confidence: 99%